400 results on '"Larsen, Annette K."'
Search Results
2. Effect of cytokines on NK cell activity and activating receptor expression in high-risk cutaneous melanoma patients
3. Comparison of antithrombin‐dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots
4. The Interaction between p53 and DNA Topoisomerase I Is Regulated Differently in Cells with Wild-Type and Mutant p53
5. Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group
6. Supplementary Figure 4 from Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
7. Supplementary Figure 2 from Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
8. Supplementary Figure 1 from Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
9. Supplementary Figure 3 from Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
10. Supplementary Figure 3 from Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status
11. Supplementary Data from Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1α Axis
12. Legend to supplementary data from Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status
13. Supplementary Figure 1 from Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status
14. Supplementary Figure 2 from Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status
15. Data from Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis
16. Data from Emergence of Drug Tolerance in Cancer Cell Populations: An Evolutionary Outcome of Selection, Nongenetic Instability, and Stress-Induced Adaptation
17. Supplementary Movie 1 from Emergence of Drug Tolerance in Cancer Cell Populations: An Evolutionary Outcome of Selection, Nongenetic Instability, and Stress-Induced Adaptation
18. Supplementary Movie 2 from Emergence of Drug Tolerance in Cancer Cell Populations: An Evolutionary Outcome of Selection, Nongenetic Instability, and Stress-Induced Adaptation
19. Supplementary Data 3 from Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis
20. Supplementary Data 1 from Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis
21. Supplementary Movie 3 from Emergence of Drug Tolerance in Cancer Cell Populations: An Evolutionary Outcome of Selection, Nongenetic Instability, and Stress-Induced Adaptation
22. Supplementary Material, Tables S1-S2 and Figures S1-S7 from Emergence of Drug Tolerance in Cancer Cell Populations: An Evolutionary Outcome of Selection, Nongenetic Instability, and Stress-Induced Adaptation
23. Supplementary Data 2 from Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell–Mediated Lysis
24. Unexpected talaroenamine derivatives and an undescribed polyester from the fungus Talaromyces stipitatus ATCC10500
25. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial
26. Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study
27. The Role of BEAMing and Digital PCR for Multiplexed Analysis in Molecular Oncology in the Era of Next-Generation Sequencing
28. A Small Molecule Screen Identifies an Inhibitor of DNA Repair Inducing the Degradation of TFIIH and the Chemosensitization of Tumor Cells to Platinum
29. Perturbations of Cellular Functions by Topoisomerase II Inhibitors : All Roads Lead to Cell Death?
30. Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status
31. Unique features of trabectedin mechanism of action
32. The C-Terminal Acidic Tail Modulates the Anticancer Properties of HMGB1
33. Osteopontin (OPN/SPP1), a Mediator of Tumor Progression, Is Regulated by the Mesenchymal Transcription Factor Slug/SNAI2 in Colorectal Cancer (CRC)
34. The DNA damage response to monofunctional anticancer DNA binders
35. The roles of DNA topoisomerase II during the cell cycle
36. The Evolution of Adjuvant Therapy in the Treatment of Early-Stage Colon Cancer
37. Replication and Homologous Recombination Repair Regulate DNA Double-Strand Break Formation by the Antitumor Alkylator Ecteinascidin 743
38. Accuracy of Predefined Hypotheses in Colon Cancer Adjuvant Phase III Trials: Observations and Recommendations
39. Targeted Therapies as Adjuvant Treatment for Early-Stage Colorectal Cancer: First Impressions and Clinical Questions
40. Functions and Clinical Implications of Autocrine VEGF Signaling in Colorectal Cancer
41. Clinical Reasons for Initiation of Adjuvant Phase III Trials on Colon Cancer
42. Osteopontin as a Regulator of Colorectal Cancer Progression and Its Clinical Applications
43. Saccharomyces cerevisiae as a model system to study the response to anticancer agents
44. In Vivo Topoisomerase I Inhibition Attenuates the Expression of Hypoxia-Inducible Factor 1α Target Genes and Decreases Tumor Angiogenesis
45. MicroRNA as Epigenetic Modifiers in Endometrial Cancer: A Systematic Review
46. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells
47. Emergence of cytotoxic resistance in cancer cell populations
48. PARPs and the DNA damage response
49. DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde?
50. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.